Evaluation of the VersaTREK System Compared to the Bactec MGIT 960 System for First-Line Drug Susceptibility Testing of Mycobacterium tuberculosis

被引：17
作者：
Espasa, M. [1 ,2 ]
Salvado, M. [1 ,3 ]
Vicente, E. [1 ,3 ]
Tudo, G.
Alcaide, F. [6 ,9 ]
Coll, P. [4 ,5 ,7 ]
Martin-Casabona, N. [8 ]
Torra, M. [1 ,2 ]
Fontanals, D. [1 ,2 ]
Gonzalez-Martin, J.
机构：
[1] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain
[2] Corp Sanitaria Parc Tauli, UDIAT CD, Lab Microbiol, Sabadell, Spain
[3] Lab Referencia Catalunya, Lab Microbiol, Barcelona, Spain
[4] Univ Barcelona, Dept Anat Patol Farmacol & Microbiol, Hosp Clin Barcelona, Serv Microbiol CDB, Barcelona, Spain
[5] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain
[6] Univ Barcelona, Dept Patol & Terapeut Expt, Barcelona, Spain
[7] Hosp Univ Santa Creu & Sant Pau, Serv Microbiol, Barcelona, Spain
[8] Hosp Univ Vall Hebron, Serv Microbiol, Barcelona, Spain
[9] Hosp Univ Bellvitge, Serv Microbiol, Lhospitalet De Llobregat, Spain
来源：
JOURNAL OF CLINICAL MICROBIOLOGY | 2012年 / 50卷 / 02期
关键词：
ANTITUBERCULOUS DRUGS; RADIOMETRIC METHOD; ESP; PYRAZINAMIDE; COMPLEX;
D O I：
10.1128/JCM.06432-11
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The aim of this study was to evaluate the reliability of the VersaTREK system for Mycobacterium tuberculosis drug susceptibility testing compared with results obtained with the Bactec MGIT 960 system. A total of 67 strains were evaluated. Overall agreement was at 98.5%. Kappa indexes were 1.0 for isoniazid, rifampin, and ethambutol, 0.937 for pyrazinamide, and 0.907 for streptomycin. The VersaTREK system is validated for M. tuberculosis drug susceptibility testing.
引用
收藏
页码：488 / 491
页数：4
相关论文
共 25 条
[1]  
[Anonymous], 2010, Global tuberculosis control 2010
[2]  
[Anonymous], 2008, WHO/HTM/TB/2008.394
[3]   Evaluation of BACTEC mycobacteria growth indicator tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis [J].
Ardito, F ;
Posteraro, B ;
Sanguinetti, M ;
Zanetti, S ;
Fadda, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) :4440-4444
[4]   Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis [J].
Aziz, Mohamed Abdel ;
Wright, Abigail ;
Laszlo, Adalbert ;
De Muynck, Aime ;
Portaels, Francois ;
Van Deun, Armand ;
Wells, Charles ;
Nunn, Paul ;
Blanc, Leopold ;
Raviglione, Mario .
LANCET, 2006, 368 (9553) :2142-2154
[5]  
Becton Dickinson, 2002, BACTEC MGIT 960 PZA
[6]  
Becton Dickinson, 2002, BACTEC MGIT 960 SIRE
[7]   Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis [J].
Bemer, P ;
Palicova, F ;
Rüsch-Gerdes, S ;
Drugeon, HB ;
Pfyffer, GE .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (01) :150-154
[8]   Evaluation of the ESP culture system II for testing susceptibilities of Mycobacterium tuberculosis isolates to four primary antituberculous drugs [J].
Bergmann, JS ;
Woods, GL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2940-2943
[9]  
Delas M A, 2001, Rev Esp Quimioter, V14, P40
[10]   WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update [J].
Falzon, D. ;
Jaramillo, E. ;
Schuenemann, H. J. ;
Arentz, M. ;
Bauer, M. ;
Bayona, J. ;
Blanc, L. ;
Caminero, J. A. ;
Daley, C. L. ;
Duncombe, C. ;
Fitzpatrick, C. ;
Gebhard, A. ;
Getahun, H. ;
Henkens, M. ;
Holtz, T. H. ;
Keravec, J. ;
Keshavjee, S. ;
Khan, A. J. ;
Kulier, R. ;
Leimane, V. ;
Lienhardt, C. ;
Lu, C. ;
Mariandyshev, A. ;
Migliori, G. B. ;
Mirzayev, F. ;
Mitnick, C. D. ;
Nunn, P. ;
Nwagboniwe, G. ;
Oxlade, O. ;
Palmero, D. ;
Pavlinac, P. ;
Quelapio, M. I. ;
Raviglione, M. C. ;
Rich, M. L. ;
Royce, S. ;
Ruesch-Gerdes, S. ;
Salakaia, A. ;
Sarin, R. ;
Sculier, D. ;
Varaine, F. ;
Vitoria, M. ;
Walson, J. L. ;
Wares, F. ;
Weyer, K. ;
White, R. A. ;
Zignol, M. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (03) :516-528
123